Replies to post #126343 on Biotech Values

[pcrutch]

I think Mitch needs to put his money where his mouth is then. If he thinks they have a chance at success, why hasn't he purchased any stock don't here at $10-11?

$DNDN CEO Gold: "Price is not the issue... Provenge is priced very fairly." He also claimed that theyre not seeing $JNJ's Zytiga creep into Provenge's labeled indication. Again, I doubt this is true.

How do they get $120 million in savings from only 500 layoffs? Seems like they were paying people pretty well with shareholders money...

Also, their ACTION study delayed over a year.